PolyPeptide Group

PolyPeptide announces results of the annual General Meeting 2024

PolyPeptide publishes invitation to the annual General Meeting 2024

PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow

PolyPeptide signs scientific collaboration agreement

PolyPeptide secures revolving credit facility

Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO

PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023

PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs

PolyPeptide announces results of the annual General Meeting 2023

PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO

PolyPeptide publishes invitation to the annual General Meeting 2023

PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023

PolyPeptide: CEO of PolyPeptide resigns

PolyPeptide signs significant commercial agreement

PolyPeptide provides market update

PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022

PolyPeptide Group provides market update

PolyPeptide Group: Monika Casanova joining PolyPeptide as CHRO and member of the PMC

PolyPeptide Group announces results of the annual General Meeting 2022

PolyPeptide publishes invitation to the annual General Meeting 2022

PolyPeptide achieves strong profitable growth in 2021

PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen

Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends

PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

PolyPeptide Group announces the exercise of the full over-allotment option

PolyPeptide Group prices IPO at CHF 64.00 per share and starts trading on the Swiss Stock Exchange

PolyPeptide Group launches IPO on the Swiss Stock Exchange and sets price range at CHF 57 to CHF 68 per share

PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange